EMA: We're firmly convinced of the benefits of the Astrazeneca vaccine

The EMA is investigating reports of blood clots following the Astrazeneca vaccine, but does not change its recommendation.


The European Medicines Agency (EMA) remains "highly convinced" that the benefits of the Astrazeneca vaccine outweigh its risks, according to EMA Executive Director Emer Cooke at a Tuesday press conference.

"We are still firmly convinced that the benefits of the Astrazeneca vaccine in preventing Covid-19 with its associated risk of hospitalization and death outweigh the risk of these side effects," she says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs